Beta-3 agonist-induced lipolysis and nitric oxide production: Relationship to PPARgamma agonist/antagonist and AMP kinase modulation

General Physiology and Biophysics

Volumn 30, Issue 1, 2011, Pages 90-99

  Hodis, Jiří ^a   Vaclavíková, Radka ^b   Farghali, Hassan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

Author keywords

Adipocytes; Beta 3 agonists; Lipolysis; Nitric oxide; PPARgamma; Troglitazone

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; ADENYLATE KINASE; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; COMPOUND C; GLYCEROL; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; MIFOBATE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DRUG ACTIVITY; DRUG POTENTIATION; GENETIC TRANSCRIPTION; INTRAABDOMINAL FAT; LIPOLYSIS; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION;

ADENYLATE KINASE; ADIPOCYTES; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANIMALS; CHROMANS; ETHANOLAMINES; GLYCEROL; LIPOLYSIS; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; ORGANOPHOSPHORUS COMPOUNDS; PPAR GAMMA; RATS; RATS, WISTAR; RECEPTOR CROSS-TALK; THIAZOLIDINEDIONES;

RATTUS;

EID: 79953686778     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: 10.4149/gpb_2011_01_90     Document Type: Article

References (48)

1. Alderton W. K., Cooper C. E., Knowles R. G. (2001): Nitric oxide synthases: structure, function and inhibition. Biochem. J. 357, 593-615 doi:10.1042/0264-6021:3570593 (Pubitemid 32735142)
2. Arner P. (2005): Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin. Endocrinol. Metab. 19, 471-482 doi: 10.1016/j.beem.2005.07.004
3. Bahr M., Spelleken M., Bock M., von Holtey M., Kiehn R., Eckel J. (1996): Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardio- myocytes. Diabetologia 39, 766-774 doi: 10.1007/s001250050509 (Pubitemid 26228105)
4. Bakopanos E., Silva J. E. (2000): Thiazolidinediones inhibit the expression of beta3-adrenergic receptors at a transcriptional level. Diabetes 49, 2108-2115 doi: 10.2337/diabetes.49.12.2108
5. Canová N. K., Lincová D., Kmoničková E., Kameníková L., Farghali H. (2006): Nitric oxide production from rat adipocytes is modulated by beta-3-adrenergic receptor agonists and is involved in a cyclic AMP-dependent lipolysis in adipocytes. Nitric Oxide 14, 200-211 doi: 10.1016/j.niox.2005.06.006
6. Carpene C., Galitzky J., Collon P., Esclapez F., Dauzats M., Lafontan M. (1993): Desensitization of beta-1 and beta-2, but not beta-3, adrenoceptor-mediated lipolytic responses of adipocytes after long-term norepinephrine infusion. J. Pharmacol. Exp. Ther. 265, 237-247
7. Daval M., Diot-Dupuy F., Bazin R., Hainault I., Viollet B., Vaulont S., Hajduch E., Ferre P., Foufelle F. (2005): Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J. Biol. Chem. 280, 25250-25257 doi: 10.1074/jbc.M414222200
8. De Groot A. A., Mathy M. J., Van Zwieten P. A., Peters S. L. (2003): Involvement of the beta-3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta. J. Cardiovasc. Pharmacol. 42, 232-236 doi: 10.1097/00005344- 200308000-00012
9. Deng T., Shan S., Li P. P., Shen Z. F., Lu X. P., Cheng J., Ning Z.Q. (2006): Peroxisome Proliferator-Activated Receptor-gamma transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1. Endocrinology 147, 875-884 doi:10.1210/en.2005-0623 (Pubitemid 43113005)
10. Deng W. G., Wu K. K. (2003): Regulation of inducible nitric oxide synthase expression by p300 and p50 acetylation. J. Immunol. 171, 6581-6588
11. Dessy C., Moniotte S., Ghisdal P., Havaux X., Noirhomme P., Balligand J. L. (2004): Endothelial beta-3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 110, 948-954 doi:10.1161/01.CIR.0000139331.85766. AF
12. Eberhardt W., Pluss C., Hummel R., Pfeilschifter J. (1998): Molecular mechanisms of inducible nitric oxide synthase gene expression by il-1b and cAMP in rat mesangial cells. J. Immunol. 160, 4961-4969 (Pubitemid 28215331)
13. Elizalde M., Ryden M., van Harmelen V., Eneroth P., Gyllenhammar H., Holm C., Ramel S., Ölund A., Arner P., Andersson K. (2000): Expression of nitric oxide synthases in subcutaneous adipose tissue of nonobese and obese humus. J. Lipid Res. 41, 1244-1251 (Pubitemid 30666890)
14. Feinstein D. L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V., Dello Russo C. (2005): Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key? Biochem. Pharmacol. 70, 177-188 doi:10.1016/j.bcp.2005.03.033 (Pubitemid 40814400)
15. Festuccia W. T., Laplante M., Berthiaume M., Gélinas Y., Deshaies Y. (2006): PPARgamma agonism increases rat adipose tissue lipolysis, expression of glyceride lipases, and the response of lipolysis to hormonal control. Diabetologia 49, 2427-2436 doi: 10.1007/s00125-006-0336-y (Pubitemid 44359105)
16. Fryer L. G., Hajduch E., Rencurel F., Salt I. P., Hundal H. S., Hardie D. G., Carling D. (2000): Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes 49, 1978-1985 doi:10.2337/diabetes.49.12.1978
17. Gardner O. S., Dewar B. J., Graves L. M. (2005): Activation of mitogen-activated protein kinases by peroxisome-proliferator-activated receptor ligands: An example of nongenomic signaling. Mol. Pharmacol. 68, 933-941 doi:10.1124/mol.105.012260
18. Garton J., Campbell D. G., Carling D., Hardie D. G., Colbran R. J., Yeamans J. (1989): Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism. Eur. J. Biochem. 179, 249-254 doi:10.1111/j.1432-1033.1989.tb14548.x
19. Gerhardt C. C., Gros J., Strosberg A. D., Issad T. ( 1999): Stimulation of the extracellular signal-regulated kinase 1/2 pathway by human beta-3 adrenergic receptor: New pharmacological profile and mechanism of activation. Mol. Pharmacol. 55, 255-262
20. Granja A. G., Sabina P., Salas M. L., Fresno M., Revilla Y. (2006): Regulation of inducible nitric oxide synthase expression by viral A238L-mediated inhibition of p65/RelA acetylation and p300 transactivation. J. Virol. 10487-10496 doi:10.1128/JVI.00862-06 (Pubitemid 44628895)
21. Granneman J. G. (1992): Effects of agonist exposure on the coupling of beta 1 and beta-3 adrenergic receptors to adenylyl cyclase in isolated adipocytes. J. Pharmacol. Exp. Ther. 261, 638-642
22. Hollenga C., Brouwer F., Zaagsma J. (1991): Differences in functional cyclic AMP compartments mediating lipolysis by isoprenaline and BRL 37344 in four adipocyte types. Eur. J. Pharmacol. 200, 325-330 doi: 10.1016/0014-2999(91) 90590-M
23. Ji J. D., Cheon H. J., Jun J. B., Choi S. J., Kim Y. R., Lee Y. H., Kim T. H., Chae I. J., Song G. G., Yoo D. H., Kim S. Y., Sohn J. (2001): Effects of peroxisome proliferator-activated receptor-gamma(PPAR-gamma) on the expression of inflammatory cytokines and apoptosis induction in rheumatoid synovial fibroblasts and monocytes. J. Autoimmun. 17, 215-221 doi: 10.1006/jaut.2001.0542 (Pubitemid 33108757)
24. Jobgen W. S., Fried S. K., Fu W. J., Meininger C. J., Wu G. (2006): Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J. Nutr. Biochem. 17, 571-588 doi:10.1016/j.jnutbio.2005.12.001
25. Kleinen H., Schwarz P. M., Förstermann U. (2003): Regulation of the expression of inducible nitric oxide synthase. Biol. Chem. 384, 1343-1364 doi:10.1515/BC.2003.152
26. Kleinert H., Pautz A., Linker K., Schwarz P. M. (2004): Regulation of the expression of inducible nitric oxide synthase. Eur. J. Pharmacol. 500, 255-266 doi: 10.1016/j.ejphar.2004.07.030
27. Knowles R. G., Moncada S. (1994): Nitric oxide synthases in mammals. Biochem. J. 298, 249-258 (Pubitemid 24072462)
28. Kurebayashi S., Xua X., Ishii S., Shiraishi M., Kouhara H., Kasayamaa S. (2005): A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-a-induced expression of vascular cell adhesion molecule-1 in vascular endothelial cells. Atherosclerosis 182, 71-77 doi:10.1016/j.atherosclerosis. 2005.02.004 (Pubitemid 41188371)
29. Lafontan M., Berlan M., Sengenes C., Moro C., Crampes F., Galitzky J. (2006): AMP- and cGMP-dependent control of lipolysis and lipid mobilization in humans: putative targets for fat cell management. In: Insights into Receptor Function and New Drug Development Targets. (Eds. M. Conn, C. Kordon and Y. Christen), pp. 53-77, Springer-Verlag, Berlin, Heidelberg doi: 10.1007/3-540-34447-0-4
30. Lambert M., Neish A. C. (1950): Rapid method for estimation of glycerol in fermentation solutions. Can. J. Res. 28, 83-89
31. LeBrasseur N. K., Kelly M., Tsao T. S., Farmer S. R., Saha A. K., Ruderman N. B., Tomas E. (2006): Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am. J. Physiol. Endocrinol. Metab. 291, E175-181 doi: 10.1152/ajpendo.00453.2005
32. Leff T. (2003): AMP-activated protein kinase regulates gene expression by direct phosphorylation of nuclear proteins. Biochem. Soc. Trans. 31, 224-227 doi:10.1042/BST0310224
33. Li M., Pascual G., Glass C. K. (2000): Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol. 20, 4699-4707 doi: 10.1128/MCB.20.13.4699-4707.2000
34. Mairal A., Langin D., Arner P., Hoffstedt. J. (2006): Human adipose triglyceride lipase (PNPLA2) is not regulated by obesity and exhibits low in vitro triglyceride hydrolase aktivity. Diabetologia 49, 1629-1636 doi: 10.1007/s00125-006-0272-x (Pubitemid 43848100)
35. Martin G., Schoonjans K., Lefebvre A.M., Staels B., Auwerx J. (1997): Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalfa and PPARgamma activators. J. Biol. Chem. 272, 28210-28217 doi: 10.1074/jbc.272.45.28210
36. Nantel F., Bonin H., Emorine L. J., Zilberfarb V., Strosberg A. D., Bouvier M., Marullo S. (1993): The human Beta-3-adrenergic receptor is resistant to short term agonist-promoted desensitization. Mol. Pharmacol. 43, 548-555
37. Nathan D. M., Buse J. B., Davidson M. B., Ferrannini E., Holman R. R., Sherwin R., Zinman B. (2009): Medical management of hyperglycemia in type 2 Diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193-203 doi:10.2337/dc08-9025
38. Pilon G., Dallaire P., Marette A. (2004): Inhibition of Inducible nitric-oxide synthase by activators of AMP-activated protein kinase. J. Biol. Chem. 279, 20767-20774 doi: 10.1074/jbc.M401390200
39. Portillo M. P., Del Barrio A. S., Garcia-Calonge M. A., Martinez J. A. (1996): Desenzitisation effect of in vivo treatment with metaproterenol on beta-1, beta-2 and beta-3-adrenergic responsiveness in rat adipocytes. Life Sci. 58, 405-414 doi: 10.1016/0024-3205(95)02305-4 (Pubitemid 26186635)
40. Ranganathan G., Unal R., Pokrovskaya I., Yao-Borengasser A., Phanavanh B., Lecka-Czernik B., Rasouli N., Kern P. A. (2006): The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. J. Lipid Res. 47, 2444-2450 doi:10.1194/jlr.M600248-JLR200 (Pubitemid 44936106)
41. Rieusset J., Touri F., Michalik L., Escher P., Desvergne B., Niesor E., Wahli W. (2002): A new selective peroxisome proliferatoractivated receptor antagonist with antiobesity and antidiabetic activity. Mol. Endocrinol. 16, 2628-2644 doi: 10.1210/me.2002-0036
42. Rodbell M. (1964): Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J. Biol. Chem. 239, 375-380
43. Shen W. J., Patel S., Yu Z., Jue D., Kraemer F. B. (2007): Effects of rosiglitazone and high fat diet on lipase/esterase expression in adipose tissue. Biochim. Biophys. Acta. 1771, 177-184
44. Schoonjans K., Peinado-Onsurbe J., Lefebvre A. M., Heyman R. A., Briggs M., Deeb S., Staels B., Auwerx J. (1996): PPARalfa and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15, 5336-5348 (Pubitemid 26336216)
45. Sullivan J. E., Brocklehurst K. J, Marley A. E., Carey F., Carling D., Beri R. K. (1994): Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett. 353, 33-36 doi:10.1016/0014-5793(94)01006-4 (Pubitemid 24312538)
46. Thomson D. M., Herway S. T., Fillmore N., Kim H., Brown J. D., Barrow J. R., Winder W. W. (2008): AMP-activated protein kinase phosphorylates transcription factors of the CREB family. J. Appl. Physiol. 104, 429-438 doi: 10.1152/japplphysiol.00900.2007
47. Vicario P. P., Candelore M. R., Schaeffer M. T., Kelly L., Thompson G. M., Brady E. J., Saperstein R., MacIntyre D. E., Tota L. M., Cascieri M. A. (1998): Desensitisation of Beta-3 -adrenergic receptor- stimulated adenylyl cyclase activity and lipolysis in rats. Life Sci. 62, 627-638 doi:10.1016/S0024-3205(97)01158-2 (Pubitemid 28045570)
48. Yin W., Mu J., Birnbaum M. J. (2003): Role of AMP-activated protein kinase in cyclic AMP-dependent lipolysis in 3T3-L1 Adipocytes. J. Biol. Chem. 278, 43074-43080 doi: 10.1074/jbc.M308484200